One noteworthy fact is that six CAR-T therapies have already been approved in China, putting the domestic market on par with that of the United States. In any biopharmaceutical subsector, this is a rare achievement.

Scientific advances such as gene editing, chimeric antigen receptor technology, and the CRISPR-Cas system are driving the rapid growth of the CGT field. The emergence of CGT is expected not only to improve therapeutic efficacy, but also to expand the scope of treatment. As a result, CGT has become a highly contested frontier in the next wave of pharmaceutical innovation, including in the United States.

However, the industrialization of China’s domestic CGT sector still faces many challenges, such as issues related to commercial payment and reimbursement. Against the backdrop of global expansion, CGT companies also need to clearly define their strategic direction.

At the recent 2nd International Biotech Innovation and Investment Conference, Tongxieyi invited Dr. Xiaohu Fan, Founder and CEO of Wondercel, and Chao Zhang, General Manager of PackGene Biotech China, to join a dialogue moderated by Zengjiang Cheng, Founder of the Tongxieyi Forum. The discussion explored the future path of CGT innovation and internationalization from multiple perspectives, including cell therapy and gene therapy, as well as biotech companies and CDMOs.